Novel trial designs like basket, umbrella, and platform trials enhance efficiency and reduce development timelines in precision medicine. Basket trials test a single therapy across different tumor ...
Hosted on MSN
Triplet combinations of immunotherapy and targeted treatments as first-line therapy for advanced renal cell carcinoma
KEYMAKER-U03 is an international, multicenter, open-label, Phase I/II umbrella trial evaluating experimental combinations of pembrolizumab-based immunotherapy and targeted treatments for advanced ...
In today’s ACT Brief, we look at how adaptive trial models are reshaping precision medicine, new data showing Wegovy’s impact ...
Results from sub-study 03A of KEYMAKER-U03, an international, open-label, rolling-arm, phase I/II umbrella trial, spotlight the promise of pembrolizumab-based regimens combined with tyrosine kinase ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback